EHS
EHS

Infantile Pompe disease with intrauterine onset: a case report and literature review | Italian Journal of Pediatrics


Classic infantile Pompe disease has a median age of onset of 2.4 (range: 0.0–12.0) months and can manifest clinical symptoms at any age [7]. Intrauterine onset of Pompe disease is extremely rare. Combined with the present case, only seven cases of Pompe disease with intrauterine onset have been reported. Despite the term “infantile” in its name, the onset occurs before birth. Pompe disease has various manifestations. Infantile cardiomyopathy mainly manifests as left ventricular myocardial hypertrophy [8]. All seven neonates showed myocardial changes on intrauterine ultrasound, but manifestations varied, including hypertrophic cardiomyopathy, dilated cardiomyopathy, and a myocardial mass. All cases eventually progressed to myocardial hypertrophy postnatally. Levels of other laboratory indicators, such as myocardial enzymes and BNP, increased to varying degrees.

Neonatal hypertrophic cardiomyopathy and hypotonia should be distinguished from other diseases, such as glycogen storage disease type IIB (Danon disease), specific fatty acid oxidation disorder, and mitochondrial respiratory chain dysfunction. These diseases have similar clinical symptoms and are mainly diagnosed based on genetic testing results [9,10,11].

All patients had GAA-related gene mutations. Although the onset was intrauterine, prenatal diagnosis using a GAA mutation analysis of the amniocentesis sample could only be obtained in one patient (case #5), owing to the positive family history. Chien et al. suggested that the treatment prognosis is better when started in the first few days of life; therefore, early diagnosis is particularly important [12]. Prenatal diagnosis could be obtained based on the laboratory finding of GAA deficiency in amniotic fluid cultures or the molecular finding of GAA mutations [13]. Pompe disease is recessively inherited, and its genetic diagnosis using chorionic villus samples can only be made if the parents are known carriers. Contamination with maternal tissue when biochemical or molecular methods are used for the diagnosis yields a false-positive result [14]. Therefore, a targeted mutational analysis should be performed to confirm the prenatal diagnosis of Pompe disease [15]. Prenatal diagnosis could not be obtained in the present case because of the unknown family history.

Currently, ERT is the cornerstone of Pompe disease management [16]. ERT can improve left ventricular function and yield better outcomes after early ERT [17]. Therefore, newborn screening for Pompe disease is of great importance [18].

We reviewed seven patients, five of whom received ERT. The time of treatment onset ranged from two hours (case #3) to two months (case #4) postnatally. Two patients did not receive treatment (cases #6 and #7). The myocardial thickness returned to normal in all patients treated with ERT, but one patient (case #2) died from respiratory failure because of infection.

Our patient had homozygous gene mutations at the same site and presented with clinical symptoms postnatally. After symptomatic treatment, vital signs stabilized for a short time, but the patient had serious developmental delay. Further, the left lung developed consolidation, and myocardial hypertrophy increased with decreasing cardiac function and severe hypotonia at six months. The mechanism of respiratory failure in patients with Pompe disease mostly involves extensive pathological changes in the muscle and nerve components of the respiratory system resulting from glycogen accumulation [19]. However, no reported patient with Pompe disease has shown homogeneous solid changes in the lungs. A completely enzyme-deficient Pompe disease-knockout mouse model showed glycogen storage in nearly all tissue and cell types [20]. Another mouse model of Pompe disease showed lysosomal glycogen accumulation in tracheal and bronchial smooth muscles [21]. Therefore, lung consolidation in patients with primary disease is considered to be related to glycogen accumulation and deposition.

Although clinical symptoms of some patients treated with ERT improved, ERT had several limitations, including the risk of immunogenicity-related complications, inability to penetrate central nervous system tissue, and requirement of life-long therapy. Further, no trial compared the effectiveness or safety of ERT with that of other interventions or placebo until 2016 [22]. Gene therapy seems promising for potential prevention, halting, and reversal of Pompe disease [19]. However, only animal experiments have been conducted, and clinical studies had a small sample size, hindering the applicability of gene therapy [1]. None of the patients we reviewed received gene therapy.

Infantile Pompe disease is a rare hereditary disease that can occur in utero, with initial signs being cardiac changes. Therefore, for fetuses with intrauterine cardiac disease, enzyme assays and genetic testing should be performed as soon as possible for early diagnosis and treatment.

This study has some limitations. First, the number of cases was small. Second, the follow-up of some patients had not been completed at the time of reporting.



Source link

EHS
Back to top button